Implementation of a Multi-Disciplinary Geriatric Oncology Clinic in Toronto, Canada
Abstract
1. Introduction
2. Materials and Methods
Clinic Description
3. Results
3.1. Baseline Characteristics
3.2. Geriatric Oncology Clinic Characteristics, Findings and Recommendations
3.3. Cancer Treatment Status and Characteristics Post-CGA
3.4. ER Visits and Hospitalizations
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Kadambi, S.; Loh, K.P.; Dunne, R.; Magnuson, A.; Maggiore, R.; Zittel, J.; Flannery, M.; Inglis, J.; Gilmore, N.; Mohamed, M.; et al. Older Adults with Cancer and Their Caregivers—Current Landscape and Future Directions for Clinical Care. Nat. Rev. Clin. Oncol. 2020, 17, 742–755. [Google Scholar] [CrossRef]
- Mohile, S.; Dale, W.; Hurria, A. Geriatric Oncology Research to Improve Clinical Care. Nat. Rev. Clin. Oncol. 2012, 9, 571–578. [Google Scholar] [CrossRef]
- Balducci, L.; Beghe, C. The Application of the Principles of Geriatrics to the Management of the Older Person with Cancer. Crit. Rev. Oncol. Hematol. 2000, 35, 147–154. [Google Scholar] [CrossRef]
- Soo, W.-K.; King, M.; Pope, A.; Parente, P.; Darzins, P.; Davis, I.D. Integrated Geriatric Assessment and Treatment (INTEGERATE) in Older People with Cancer Planned for Systemic Anticancer Therapy. J. Clin. Oncol. 2020, 38, 12011. [Google Scholar] [CrossRef]
- Scher, K.S.; Hurria, A. Under-Representation of Older Adults in Cancer Registration Trials: Known Problem, Little Progress. J. Clin. Oncol. 2012, 30, 2036–2038. [Google Scholar] [CrossRef]
- Talarico, L.; Chen, G.; Pazdur, R. Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration. J. Clin. Oncol. 2004, 22, 4626–4631. [Google Scholar] [CrossRef] [PubMed]
- Okoli, G.N.; Stirling, M.; Racovitan, F.; Lam, O.L.; Reddy, V.K.; Copstein, L.; Hsu, T.; Abou-Setta, A.M.; Dawe, D.E. Integration of Geriatric Assessment into Clinical Oncology Practice: A Scoping Review. Curr. Probl. Cancer 2021, 45, 100699. [Google Scholar] [CrossRef] [PubMed]
- López-Otín, C.; Pietrocola, F.; Roiz-Valle, D.; Galluzzi, L.; Kroemer, G. Meta-Hallmarks of Aging and Cancer. Cell Metab. 2023, 35, 12–35. [Google Scholar] [CrossRef] [PubMed]
- Bumanlag, I.M.; Jaoude, J.A.; Rooney, M.K.; Taniguchi, C.M.; Ludmir, E.B. Exclusion of Older Adults from Cancer Clinical Trials: Review of the Literature and Future Recommendations. Semin. Radiat. Oncol. 2022, 32, 125–134. [Google Scholar] [CrossRef] [PubMed]
- 2008 National Health Interview Survey. Percent of US Adults 55 and Over with Chronic Conditions. 2008, p. 76. Available online: https://ftp.cdc.gov/pub/health_statistics/nchs/Dataset_Documentation/NHIS/2008/srvydesc.pdf (accessed on 28 January 2025).
- Hurria, A.; Levit, L.A.; Dale, W.; Mohile, S.G.; Muss, H.B.; Fehrenbacher, L.; Magnuson, A.; Lichtman, S.M.; Bruinooge, S.S.; Soto-Perez-de-Celis, E.; et al. Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement. J. Clin. Oncol. 2015, 33, 3826–3833. [Google Scholar] [CrossRef]
- Kristjansson, S.R.; Farinella, E.; Gaskell, S.; Audisio, R.A. Surgical Risk and Post-Operative Complications in Older Unfit Cancer Patients. Cancer Treat. Rev. 2009, 35, 499–502. [Google Scholar] [CrossRef] [PubMed]
- Dale, W.; Klepin, H.D.; Williams, G.R.; Alibhai, S.M.H.; Bergerot, C.; Brintzenhofeszoc, K.; Hopkins, J.O.; Jhawer, M.P.; Katheria, V.; Loh, K.P.; et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update. J. Clin. Oncol. 2023, 41, 4293–4312. [Google Scholar] [CrossRef] [PubMed]
- Caillet, P.; Laurent, M.; Bastuji-Garin, S.; Liuu, E.; Lagrange, J.-L.; Culine, S.; Canoui-Poitrine, F.; Paillaud, E. Optimal Management of Elderly Cancer Patients: Usefulness of the Comprehensive Geriatric Assessment. Clin. Interv. Aging 2014, 9, 1645–1660. [Google Scholar] [CrossRef] [PubMed]
- Stuck, A.E.; Siu, A.L.; Wieland, G.D.; Rubenstein, L.Z.; Adams, J. Comprehensive Geriatric Assessment: A Meta-Analysis of Controlled Trials. Lancet 1993, 342, 1032–1036. [Google Scholar] [CrossRef] [PubMed]
- Frese, T.; Deutsch, T.; Keyser, M.; Sandholzer, H. In-Home Preventive Comprehensive Geriatric Assessment (CGA) Reduces Mortality—A Randomized Controlled Trial. Arch. Gerontol. Geriatr. 2012, 55, 639–644. [Google Scholar] [CrossRef] [PubMed]
- Extermann, M.; Aapro, M.; Bernabei, R.; Cohen, H.J.; Droz, J.-P.; Lichtman, S.; Mor, V.; Monfardini, S.; Repetto, L.; Sørbye, L.; et al. Use of Comprehensive Geriatric Assessment in Older Cancer Patients. Crit. Rev. Oncol. Hematol. 2005, 55, 241–252. [Google Scholar] [CrossRef]
- Li, D.; Sun, C.-L.; Kim, H.; Soto-Perez-de-Celis, E.; Chung, V.; Koczywas, M.; Fakih, M.; Chao, J.; Cabrera Chien, L.; Charles, K.; et al. Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer. JAMA Oncol. 2021, 7, e214158. [Google Scholar] [CrossRef] [PubMed]
- Mohile, S.G.; Mohamed, M.R.; Xu, H.; Culakova, E.; Loh, K.P.; Magnuson, A.; Flannery, M.A.; Obrecht, S.; Gilmore, N.; Ramsdale, E.; et al. Evaluation of Geriatric Assessment and Management on the Toxic Effects of Cancer Treatment (GAP70+): A Cluster-Randomised Study. Lancet 2021, 398, 1894–1904. [Google Scholar] [CrossRef] [PubMed]
- Kalsi, T.; Babic-Illman, G.; Ross, P.J.; Maisey, N.R.; Hughes, S.; Fields, P.; Martin, F.C.; Wang, Y.; Harari, D. The Impact of Comprehensive Geriatric Assessment Interventions on Tolerance to Chemotherapy in Older People. Br. J. Cancer 2015, 112, 1435–1444. [Google Scholar] [CrossRef] [PubMed]
- Yesavage, J.A.; Brink, T.L.; Rose, T.L.; Lum, O.; Huang, V.; Adey, M.; Leirer, V.O. Development and Validation of a Geriatric Depression Screening Scale: A Preliminary Report. J. Psychiatr. Res. 1982, 17, 37–49. [Google Scholar] [CrossRef]
- Wallace, M.; Shelkey, M.; Hartford Institute for Geriatric Nursing. Katz Index of Independence in Activities of Daily Living (ADL). Urol. Nurs. 2007, 27, 93–94. [Google Scholar] [PubMed]
- Graf, C. The Lawton Instrumental Activities of Daily Living Scale. AJN Am. J. Nurs. 2008, 108, 52–62. [Google Scholar] [CrossRef] [PubMed]
- Rockwood, K.; Theou, O. Using the Clinical Frailty Scale in Allocating Scarce Health Care Resources. Can. Geriatr. J. 2020, 23, 254–259. [Google Scholar] [CrossRef]
- Hurria, A.; Togawa, K.; Mohile, S.G.; Owusu, C.; Klepin, H.D.; Gross, C.P.; Lichtman, S.M.; Gajra, A.; Bhatia, S.; Katheria, V.; et al. Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study. J. Clin. Oncol. 2011, 29, 3457–3465. [Google Scholar] [CrossRef] [PubMed]
- Nasreddine, Z.S.; Phillips, N.A.; Bédirian, V.; Charbonneau, S.; Whitehead, V.; Collin, I.; Cummings, J.L.; Chertkow, H. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J. Am. Geriatr. Soc. 2005, 53, 695–699. [Google Scholar] [CrossRef] [PubMed]
- Kurlowicz, L.; Wallace, M. The Mini-Mental State Examination (MMSE). J. Gerontol. Nurs. 1999, 25, 8–9. [Google Scholar] [CrossRef] [PubMed]
- Storey, J.E.; Rowland, J.T.J.; Conforti, D.A.; Dickson, H.G. The Rowland Universal Dementia Assessment Scale (RUDAS): A Multicultural Cognitive Assessment Scale. Int. Psychogeriatr. 2004, 16, 13–31. [Google Scholar] [CrossRef]
- Borson, S.; Scanlan, J.; Brush, M.; Vitaliano, P.; Dokmak, A. The Mini-Cog: A Cognitive “vital Signs” Measure for Dementia Screening in Multi-Lingual Elderly. Int. J. Geriatr. Psychiatry 2000, 15, 1021–1027. [Google Scholar] [CrossRef] [PubMed]
- Verduzco-Aguirre, H.C.; Navarrete-Reyes, A.P.; Chavarri-Guerra, Y.; Ávila-Funes, J.A.; Soto-Perez-de-Celis, E. The Effect of a Geriatric Oncology Clinic on Treatment Decisions in Mexican Older Adults With Cancer. J. Am. Geriatr. Soc. 2019, 67, 992–997. [Google Scholar] [CrossRef]
- Sourdet, S.; Brechemier, D.; Steinmeyer, Z.; Gerard, S.; Balardy, L. Impact of the Comprehensive Geriatric Assessment on Treatment Decision in Geriatric Oncology. BMC Cancer 2020, 20, 384. [Google Scholar] [CrossRef]
- Luciani, A.; Jacobsen, P.B.; Extermann, M.; Foa, P.; Marussi, D.; Overcash, J.A.; Balducci, L. Fatigue and Functional Dependence in Older Cancer Patients. Am. J. Clin. Oncol. 2008, 31, 424–430. [Google Scholar] [CrossRef] [PubMed]
- Corre, R.; Greillier, L.; Le Caër, H.; Audigier-Valette, C.; Baize, N.; Bérard, H.; Falchero, L.; Monnet, I.; Dansin, E.; Vergnenègre, A.; et al. Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study. J. Clin. Oncol. 2016, 34, 1476–1483. [Google Scholar] [CrossRef] [PubMed]
- Garric, M.; Sourdet, S.; Cabarrou, B.; Steinmeyer, Z.; Gauthier, M.; Ysebaert, L.; Beyne-Rauzy, O.; Gerard, S.; Lozano, S.; Brechemier, D.; et al. Impact of a Comprehensive Geriatric Assessment on Decision-making in Older Patients with Hematological Malignancies. Eur. J. Haematol. 2021, 106, 616–626. [Google Scholar] [CrossRef]
- Magnuson, A.; Mohile, S.; Janelsins, M. Cognition and Cognitive Impairment in Older Adults with Cancer. Curr. Geriatr. Rep. 2016, 5, 213–219. [Google Scholar] [CrossRef] [PubMed]
Total | |
---|---|
(n = 100) | |
Age | |
Median (Range) | 80 (63–97) |
Sex | |
Female | 70 (70%) |
Male | 30 (30%) |
Cancer type (n = 106) a | |
Breast | 33 (31%) |
Gastrointestinal | 27 (25%) |
Skin | 14 (13%) |
Lung | 10 (9%) |
Malignant hematology | 8 (8%) |
Genitourinary | 8 (8%) |
Gynecologic | 3 (3%) |
Head and neck | 3 (3%) |
Cancer stage (n = 106) a | |
Early stage (I-III) | 52 (49%) |
Advanced stage (IV) | 49 (46%) |
No proven cancer—IPMN | 3 (3%) |
N/A—Suspected MDS or MDS/MPN overlap | 2 (2%) |
Number of active and past medical conditions | |
Median (Interquartile range) | 7 (5, 10) |
Pre-existing conditions of interest | |
Depression | 18 (18%) |
Delirium | 9 (9%) |
Dementia/cognitive impairment | 6 (6%) |
Number of current medications | |
Median (Interquartile range) | 7 (4, 10) |
Cancer treatment status at the time of CGA | |
On treatment b | 41 (41%) |
Considering treatment | 29 (29%) |
On surveillance | 25 (25%) |
Current treatment on hold | 5 (5%) |
Type of cancer treatment at time of CGA (n = 52) c | |
Endocrine therapy | 21 (40%) |
Chemotherapy | 16 (31%) |
Immunotherapy | 10 (19%) |
Targeted therapy | 4 (8%) |
Radiation | 1 (2%) |
Dosing of current treatment (n = 46) | |
Ideal dose | 27 (59%) |
Reduced | 16 (35%) |
Increased | 2 (4%) |
N/A | 1 (2%) |
Total | |
---|---|
(n = 100) | |
Proportion of patients seen | 100/103 (97%) |
Time frame seen, days | |
Median (Interquartile range) | 21 (14, 33) |
Sensitivity Analysis—Time frame seen, days (n = 94) d | |
Median (Interquartile range) | 18 (13, 31) |
Treatment candidate patients—Time frame seen, days (n = 33) | |
Median (Interquartile range) | 15 (10, 18) |
Patients seen within target requested | 54 (54%) |
Reasons not seen within target (n = 46) | |
Earliest slot available | 35 (76%) |
Clinic understaffed | 4 (9%) |
Patient/patient’s family requested to rebook | 2 (4%) |
Clinic closure | 2 (4%) |
Delayed due to awaiting investigations | 1 (2%) |
Administrative delay | 1 (2%) |
Unknown | 1 (2%) |
Specialty of referring physician | |
Medical oncology | 77 (77%) |
Surgery | 13 (13%) |
Radiation oncology | 6 (6%) |
Malignant hematology | 3 (3%) |
Palliative medicine | 1 (1%) |
Reasons for referral (n = 150) e | |
Cognitive decline | 48 (32%) |
Treatment candidate | 33 (22%) |
Functional decline/Frailty | 22 (15%) |
Mobility/Falls | 19 (13%) |
Multi-morbidity | 8 (5%) |
Polypharmacy | 5 (3%) |
Mood/Behaviour | 3 (2%) |
Medical optimization prior to surgery | 2 (1%) |
General assessment | 2 (1%) |
Other f | 8 (5%) |
Pre-assessments | |
Pharmacy (n = 100) | 86 (86%) |
Occupational therapy (n = 54) g | 34 (63%) |
Nursing (n = 46) g | 36 (78%) |
Abnormal cognitive screen result | |
MOCA (n = 60) | 46 (77%) |
RUDAS (n = 16) | 5 (31%) |
MMSE (n = 5) | 2 (40%) |
Mini-Cog (n = 2) | 0 (00%) |
Abnormal GDS score (n = 78) h | 20 (26%) |
Clinical Frailty Score (n = 76) | |
Median (Interquartile range) | 5 (4, 6) |
ADL score deficits | |
Median (Interquartile range) | 0 (0, 2) |
IADL score deficits | |
Median (Interquartile range) | 2.5 (1, 5) |
New diagnoses (n = 84) i | |
Cognition | 55 (65%) |
Cardiac | 10 (12%) |
Depression | 7 (8%) |
Neurological | 6 (7%) |
Renal | 3 (4%) |
Endocrine | 2 (2%) |
Respiratory | 1 (1%) |
Type of specialist physician referrals (n = 24) j | |
Psychiatry | 6 (25%) |
Cardiology | 4 (17%) |
Ophthalmology | 4 (17%) |
Palliative care | 3 (13%) |
Neurology | 3 (13%) |
Urology | 1 (4%) |
Rheumatology | 1 (4%) |
Thromboembolism clinic | 1 (4%) |
Urogynecology | 1 (4%) |
Medication changes made | 47 (47%) |
Tests requested | |
Labs | 47 (47%) |
Imaging | 41 (41%) |
Cardiac tests | 18 (18%) |
EMG | 1 (1%) |
Total | |
---|---|
(n = 100) | |
Continuation of treatment after CGA (n = 46) | 35 (76%) |
Continuation of treatment and started new treatment after CGA (n = 46) | 3 (7%) |
Only started a new treatment after CGA (n = 54) | 29 (54%) |
Patients not on treatment before or after CGA | 22 (22%) |
Patients referred to determine suitability for treatment | |
Recommendations for/against cancer treatment (n = 33) k | |
Suitable for treatment | 16 (48%) |
Suitable for treatment with modification | 10 (30%) |
Concern/against treatment | 7 (21%) |
Referring MD that followed through with the recommendation (n = 33) | 31 (94%) |
Cancer treatment status within 6 months after CGA (n = 33) | |
On treatment | 25 (76%) |
Not on treatment | 8 (24%) |
Type of cancer treatment within 6 months after CGA (n = 33) l | |
Chemotherapy | 17 (50%) |
Immunotherapy | 6 (18%) |
Endocrine therapy | 3 (9%) |
Radiation | 4 (12%) |
Surgery | 4 (12%) |
Targeted therapy | 1 (3%) |
Dosing of treatment (n = 25) | |
No change | 9 (36%) |
Reduced | 10 (40%) |
Increased | 0 (0%) |
N/A | 6 (24%) |
Patients not referred to determine suitability for treatment | |
Cancer treatment status within 6 months after CGA (n = 67) | |
On treatment | 44 (66%) |
Not on treatment | 23 (34%) |
Type of cancer treatment within 6 months after CGA (n = 50) m | |
Chemotherapy | 11 (22%) |
Immunotherapy | 8 (16%) |
Endocrine therapy | 21 (42%) |
Radiation | 3 (6%) |
Surgery | 3 (6%) |
Targeted therapy | 4 (8%) |
Dosing of treatment (n = 43) | |
No change | 24 (56%) |
Reduced | 13 (30%) |
Increased | 2 (5%) |
N/A | 4 (9%) |
Total | |
---|---|
(n = 100) | |
ER visits within 6 months of CGA | |
Number of ER visits per patient | |
Median (Interquartile range) | 0 (0, 1) |
Reason for first ER visit (n = 34) n | |
Cancer-related | 12 (35%) |
Comorbidity-related | 12 (35%) |
Treatment-related | 4 (12%) |
Infection-related | 4 (12%) |
Other | 2 (6%) |
Reason for second/third ER visit (n = 10) o | |
Cancer-related | 3 (30%) |
Comorbidity-related | 3 (30%) |
Treatment-related | 1 (10%) |
Infection-related | 3 (30%) |
Hospitalizations within 6 months of CGA | |
Number of hospitalizations per patient | |
Median (Interquartile range) | 0 (0, 1) |
Length of stay, days (n = 40) | |
Median (Interquartile range) | 7 (3, 12) |
Reason for first hospitalization (n = 32) p | |
Cancer-related | 16 (50%) |
Infection-related | 7 (22%) |
Comorbidity-related | 6 (19%) |
Treatment-related | 3 (9%) |
Discharge location after first hospitalization (n = 30) | |
Home with support services | 10 (33%) |
Home without support services | 12 (40%) |
Palliative care unit (Sunnybrook) | 4 (13%) |
Deceased | 3 (10%) |
Unknown | 1 (3%) |
Reason for second/third hospitalization (n = 10) q | |
Cancer-related | 4 (40%) |
Comorbidity-related | 4 (40%) |
Infection-related | 1 (10%) |
Treatment-related | 1 (10%) |
Discharge location after second/third hospitalization (n = 10) q | |
Home with support services | 1 (10%) |
Home without support services | 3 (30%) |
Rehab facility | 2 (20%) |
Deceased | 4 (4%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Menjak, I.B.; Campos, K.; Pasetka, M.; Budden, A.; Curle, E.; Gibson, L.; Szumacher, E.; Mehta, R. Implementation of a Multi-Disciplinary Geriatric Oncology Clinic in Toronto, Canada. Curr. Oncol. 2025, 32, 89. https://doi.org/10.3390/curroncol32020089
Menjak IB, Campos K, Pasetka M, Budden A, Curle E, Gibson L, Szumacher E, Mehta R. Implementation of a Multi-Disciplinary Geriatric Oncology Clinic in Toronto, Canada. Current Oncology. 2025; 32(2):89. https://doi.org/10.3390/curroncol32020089
Chicago/Turabian StyleMenjak, Ines B., Khloe Campos, Mark Pasetka, Arlene Budden, Elaine Curle, Leslie Gibson, Ewa Szumacher, and Rajin Mehta. 2025. "Implementation of a Multi-Disciplinary Geriatric Oncology Clinic in Toronto, Canada" Current Oncology 32, no. 2: 89. https://doi.org/10.3390/curroncol32020089
APA StyleMenjak, I. B., Campos, K., Pasetka, M., Budden, A., Curle, E., Gibson, L., Szumacher, E., & Mehta, R. (2025). Implementation of a Multi-Disciplinary Geriatric Oncology Clinic in Toronto, Canada. Current Oncology, 32(2), 89. https://doi.org/10.3390/curroncol32020089